WEE1 and neutropenia: Other than palbociclib which was strongly associated with neutropenia and granulocytopenia, the second cluster contained drugs that were poorly associated with these adverse events, such as protein kinase agents (e.g., regorafenib and imatinib) and immune checkpoint inhibitors (e.g., nivolumab and ipilimumab).